Foamix Pharmaceuticals Ltd. (FOMX) Trading 4.2% Higher
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) shares traded up 4.2% during mid-day trading on Monday . The stock traded as high as $6.93 and last traded at $6.87, with a volume of 210,942 shares traded. The stock had previously closed at $6.59.
Several research analysts have issued reports on the company. Zacks Investment Research downgraded Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th. Guggenheim reiterated a “buy” rating and set a $10.00 target price on shares of Foamix Pharmaceuticals in a research report on Tuesday, May 10th.
The company’s 50 day moving average is $6.57 and its 200 day moving average is $6.59. The firm’s market capitalization is $203.56 million.
Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.08. On average, equities analysts forecast that Foamix Pharmaceuticals Ltd. will post ($0.89) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Foamix Pharmaceuticals stock. J. Goldman & Co LP boosted its position in shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) by 22.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 580,000 shares of the specialty pharmaceutical company’s stock after buying an additional 105,190 shares during the period. J. Goldman & Co LP owned 1.90% of Foamix Pharmaceuticals worth $4,704,000 as of its most recent SEC filing.
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.